Excerpts

Variables showing a tendency toward statistical significance ( p < 0.1) in the univariable model were entered into the multivariable model.

In this context, our exploratory analysis suggested that PTV volume (>13 cc) was marginally significant ( p < 0.1) for toxicity, but this requires validation in the full cohort of 55 patients.

The second included 25 studies with 50,404 patients; the RATS group reported longer DFS than the VATS group (HR 0.76, 95% CI 0.59–0.97; p = 0.03) and a nonsignificant trend toward longer OS (HR 0.77, 95% CI 0.57–1.05; p = 0.10) [ 117 ].

Covariates that were significant or close to significance on univariable analysis (Chi square, p < 0.10) were included in multivariable logistic regression to predict peritoneal surface recurrence.

Factors showing at least borderline significance ( p < 0.1) in univariate Cox proportional hazards analyses for overall survival (OS) were included in subsequent multivariate analysis.

Statistical significance was set at p -value < 0.05, while statistical trend (marginal significance) was set at 0.05 < p -value < 0.1.

Furthermore, the expression of some of the genes significantly or almost significantly changed ( t -test, p ≤ 0.10) following starvation, with biggest changes occurring in the expression of SNX18, HMGB1, Tp53inp2, and RICTOR ( Figure 8 B).

There was a statistical trend favoring ATEs in patients with “extensive disease” (OR 5.3. p = 0.10) or elevated LDH (OR 3.4, p = 0.10), while no association was found with chemotherapy protocol (especially cisplatin vs. carboplatin, OR 2.12, p = 0.69), histology, or high blood pressure.

The model with the additional covariates showed marginal significance (at p < 0.10) for social participation ( p = 0.079).

The variables with significance or borderline significance ( p < 0.1) in the univariate analyses and those considered relevant from the literature were included in a multivariate regression model using stepwise backward selection.

In terms of the time to MB or CRB, rivaroxaban showed a trend of being a risk factor for MB (HR 3.89; p = 0.104) and CRB (HR 2.37; p = 0.102) compared to dalteparin ( Table S2 ).

Furthermore, PSA density > 0.20 ng/mL 2 showed a trend toward significance (OR = 1.73, 95% CI: 0.89–3.36, p = 0.106), as did D’Amico intermediate/high-risk classification (OR = 1.89, 95% CI: 0.97–3.68, p = 0.061).

Furthermore, treatment techniques had a trend towards significance in different CEUS LI-RADS groups with LR-3 HCC more frequently submitted to TACE (or percutaneous treatment) than the HCC in the other LR groups ( p = 0.107). 2.3.

Elevated miR-122 only showed a slight trend toward favorable survival rates ( p = 0.108 for OS and p = 0.036 for DFS) ( Figure 6 B).

Further, our subgroup analysis failed to detect a statistically significant association between OS and the PLR in eCCA patients with marginally non-significant values (HR = 1.37, 95% CI = 0.93–2.03, p = 0.11).

Mean kurtosis of v e and skewness of τ i values showed a borderline significant difference between the groups ( p = 0.11 for v e and p = 0.09 for τ i ).

10.64%; p = 0.07), showing a trend towards significance, and a lower rate of no response to the treatment (38.64% vs. 61.36%; p = 0.11).

The all-cause 30-day mortality of the entire cohort was 6.3%, not significantly different between treatment groups, although an increasing trend for DEC (AZA 3.8%, DEC 8.9%; p = 0.111) was found.

For example, a randomized controlled trial ( n = 98) reported that the rate of one-year ovarian failure was significantly reduced from 80.6% in the chemotherapy-alone group to 44.7% in the GnRHa group ( p = 0.002), with benefit observed across HR+ and HR− subgroups, though statistical significance was reached only in the HR+ subgroup ( p = 0.029); the HR− subgroup showed a numerical trend that did not reach significance ( p = 0.111) [ 32 ].

However, patients with high 53BP1 scores obtained after the start of the treatment and during the final visits showed an increasing trend of longer PFS (1st treatment visits: P = 0.113; final visits: P = 0.065).

While fmTLS + sarcomas showed a favorable trend towards prolonged time to distant progression (TTDP) at 5-years, this did not reach statistical significance ( p = 0.115) ( Figure 3 C).

Patients with progression to the first treatment showed a trend towards shorter PFS, which was not statistically significant (4.5 months [95% CI: 2.4–6.6 months] vs. 7 months [95% CI: 1.6–12.4 months], p = 0.116).

Total Neoadjuvant Therapy In a cohort of 85 LARC patients (many of whom were treated with TNT) undergoing serial plasma ctDNA assessments, TNT showed a trend towards an increased tumor response (odds ratio or OR 2.9, 95% CI 0.8–12.3, p = 0.1178), but there was no association between pre-neoadjuvant therapy and post-neoadjuvant therapy ctDNA status and tumor response [ 57 ].

NR, HR 0.29 CI 95% 0.10–0.86, p = 0.02) and a trend towards significance in PFS (5.0 vs. 14.2 months, HR 0.43, CI 95% 0.15–1.25, p = 0.12) ( Figure 1 e).

A favorable trend was also observed for ORR (52.5% vs. 35.1%, p = 0.12) and OS (20.0 vs. 8.8 months; HR: 0.62; 95% CI: 0.35–1.10; p = 0.10) ( Figure 3 B).